Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles

We identified constitutional truncating mutations of the BRCA1-interacting helicase BRIP1 in 9/1,212 individuals with breast cancer from BRCA1/BRCA2 mutation–negative families but in only 2/2,081 controls (P = 0.0030), and we estimate that BRIP1 mutations confer a relative risk of breast cancer of 2.0 (95% confidence interval = 1.2–3.2, P = 0.012). Biallelic BRIP1 mutations were recently shown to cause Fanconi anemia complementation group J. Thus, inactivating truncating mutations of BRIP1, similar to those in BRCA2, cause Fanconi anemia in biallelic carriers and confer susceptibility to breast cancer in monoallelic carriers.

[1]  Hans Joenje,et al.  Biallelic Inactivation of BRCA2 in Fanconi Anemia , 2002, Science.

[2]  C. Mathew,et al.  The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J , 2005, Nature Genetics.

[3]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[4]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[5]  D. Sgroi,et al.  BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function , 2001, Cell.

[6]  S. Cantor,et al.  Assessing the Link between BACH1 and BRCA1 in the FA Pathway , 2006, Cell cycle.

[7]  S. Seal,et al.  Evaluation of Fanconi Anemia genes in familial breast cancer predisposition. , 2003, Cancer research.

[8]  S. Cantor,et al.  BACH1 is a DNA repair protein supporting BRCA1 damage response , 2006, Oncogene.

[9]  S. Seal,et al.  Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour , 2005, Journal of Medical Genetics.

[10]  J. Ott,et al.  The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia , 2005, Nature Genetics.

[11]  M. Swift,et al.  Reassessment of cancer predisposition of Fanconi anemia heterozygotes. , 1980, Journal of the National Cancer Institute.

[12]  S. Cantor,et al.  BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. , 2005, Cancer cell.

[13]  A. D’Andrea,et al.  Molecular pathogenesis of Fanconi anemia: recent progress. , 2006, Blood.

[14]  N E Day,et al.  Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population‐based study , 2001, Genetic epidemiology.

[15]  D. Livingston,et al.  The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. , 2004, Proceedings of the National Academy of Sciences of the United States of America.